Nisar Ahmad, Lixue Chen, Zixi Yuan, Xiaodong Ma, Xiaobo Yang, Yinan Wang, Yongshun Zhao, Huan Jin, Najib Khaidamah, Jinan Wang, Jiashuo Lu, Ziqi Liu, Moli Wu, Qian Wang, Yan Qi, Chong Wang, Yupu Zhao, Yang Piao, Rujie Huang, Yunpeng Diao, Sa Deng, Xiaohong Shu
Glioblastoma (GBM) is a brain tumor characterized by its aggressive and invasive properties. It is found that STAT3 is abnormally activated in GBM, and inhibiting STAT3 signaling can effectively suppress tumor progression. In this study, novel pyrimidine compounds, BY4003 and BY4008, were synthesized to target the JAK3/STAT3 signaling pathway, and their therapeutic efficacy and mechanisms of action were evaluated and compared with Tofacitinib in U251, A172, LN428 and patient-derived glioblastoma cells. The ADP-Glo™ kinase assay was utilized to assessed the inhibitory effects of BY4003 and BY4008 on JAK3, a crucial member of the JAK family...
August 16, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics